May 31- June 1, 2023

Consortium of Multiple Sclerosis Centers

Presentations

June 1-4

Consortium of Multiple Sclerosis Centers

Presentations

 

Consortium of Multiple Sclerosis Centers

Presentations

Ofatumumab – B Cell Therapy
Ofatumumab Efficacy & Safety

Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis Patients who had Breakthrough Disease Activity on Oral Fumarates or Fingolimod: An Interim Analysis of ARTIOS

Bove R. et.al
Poster Presentation: LB10
Abstract

Effect of Longer-term Ofatumumab Treatment on Disability Worsening and Brain Volume Change

Robertson DS et.al
Poster Presentation: DMT27
Abstract

Pregnancy Outcomes Following Exposure to Ofatumumab in Patients With MS: Results From the PRIM Study

Bove R. et.al
Poster Presentation: DMT49
Abstract

Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis

Cohen JA et.al
Poster Presentation: DMT32
Abstract

Baseline Characteristics and 6-Month Tolerability, Safety and Persistence in a Real-World Cohort of Multiple Sclerosis Patients Initiating Ofatumumab

Amin M et.al
Poster Presentation: DMT47
Abstract

Real-world persistence and adherence to ofatumumab versus other self-injectable disease modifying therapies (DMTs) in patients with multiple sclerosis (MS)

Gorritz M et.al
Poster Presentation: DMT25
Abstract

Real-World Satisfaction and Experience With Injection and Autoinjector Device for Ofatumumab Indicated for Multiple Sclerosis

Perrin Ross A et.al
Poster Presentation: LB09
Abstract

Real-world persistence of ofatumumab versus oral disease modifying therapies (DMTs) in patients with multiple sclerosis (MS)

Gorritz M et.al
Poster Presentation: LB15
Abstract
Remibrutinib – BTK inhibitor
Remibrutinib Safety

Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders

Williams M et.al
Poster Presentation: DMT46
Abstract

MLR ID: 285529

Ofatumumab – B Cell Therapy
Ofatumumab & COVID-19 Vaccination

[DMT36] COVID-19 Outcomes and Vaccination Status in Patients With Relapsing Multiple Sclerosis Receiving Ofatumumab

Winthrop K. et.al
Abstract
Ofatumumab Efficacy & Safety

[DMT04] Long-term safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis

Nicholas J. et.al
Abstract

[DMT11] Effect of Ofatumumab on Lymphocytes and Neutrophils in Patients with Relapsing Multiple Sclerosis Over 4 Years

Bar-Or A. et.al
Abstract

[DMT20] Longer-Term Effects of Ofatumumab on Clinical and MRI Outcomes in Patients with Relapsing Multiple Sclerosis

Robertson D. et.al
Abstract

[DMT28] SOSTOS Study Design: Assessing Transition to Ofatumumab from Other Disease-Modifying Therapies in RRMS After Elevation of Serum Neurofilament Light Levels

Cox G. et al.
Abstract

[DMT33] Injection-related reactions with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: Data from clinical studies and post marketing experience

Kramer J. et.al
Abstract

[DMT47] Ofatumumab Improves NEDA-3 Likelihood Compared With Teriflunomide in Black/African American Patients With Relapsing MS: Subgroup Analysis of the ASCLEPIOS Studies

Williams M. et.al
Abstract

[DMT49] Real-World Utilization of Ofatumumab for Treatment of Multiple Sclerosis (MS): Trends Nine Months after FDA Approval

Coyle PK.et al
Abstract

[DMT55] A Systematic Literature Review of Immunoglobulin Levels Among B-Cell–Depleting Therapies and Risk of Infections in Relapsing Multiple Sclerosis

Saidha S, et al
Abstract

[DMT56] Ofatumumab Improves NEDA-3 Likelihood in Hispanic/Latino Patients Compared With Teriflunomide in Relapsing Multiple Sclerosis: Subgroup Analysis of the ASCLEPIOS Studies

Delgado S. et.al
Abstract

[LB8385] Efficacy of Ofatumumab in Treatment-Naïve, First-Switch, and Late-Switch Patients: Insights From the ALITHIOS Open-Label Extension Study

Jaffrey C. et al.
Abstract
Ofatumumab & Pregnancy

[DMT35] Pregnancy outcomes in patients with multiple sclerosis

Hellwig K. et.al
Abstract
Siponimod - S1P Receptor Modulator
Siponimod & COVID-19 Vaccination

[DMT12] Evaluating Humoral Immune Response to mRNA COVID-19 Vaccines in Siponimod-treated Patients with Advancing Forms of RMS: A COVID-19 Vaccine Sub-study of the EXCHANGE Trial

Bar-Or A. et.al
Abstract
MS Treatment & Care

[DMT51] Identifying signs of progression in people diagnosed with multiple sclerosis using administrative health care claims data

Berkovich R. et al
Abstract

[LB8384] Wearing-off Effect Towards the End of Treatment Cycles in MS Patients Receiving High-efficacy DMTs–Data from Social Media Listening

Fielding J. et.al
Abstract

MLR ID: 215633

October 25-28,2021, Virtual Meeting
 

SIPONIMOD

Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties

Poster Presentation: 7319
Abstract

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations:Expand Study Data up to 5 Years

Poster Presentation: 7322
Abstract

Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World

Poster Presentation: 7704
Abstract

Development and Usability Testing of a Patient- Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Oral Presentation: DXM01
Abstract Oral Presentation

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the EXPAND Study

Poster Presentation: DMT41
Abstract

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND study

Poster Presentation: DMT54
Abstract

Long-term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the EXPAND Study up to 5 Years

Poster Presentation: DMT56
Abstract

Safety and Efficacy of Siponimod in Patients With Active Secondary Progressive Multiple Sclerosis Identifying as Hispanic from the EXPAND Study

Poster Presentation: DMT66
Abstract

OFATUMUMAB

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data

Poster Presentation: 7302
Abstract

Evaluating Perceptions of Ofatumumab in Multiple Sclerosis via Social Media Listening– Early 3 Months Post Approval Data

Poster Presentation: 7329
Abstract

Interim Results of Open-label Multicenter Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients With Relapsing Multiple Sclerosis Treated With Ofatumumab

Poster Presentation: 7837
Abstract

Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: ARTIOS Phase 3b Study Design

Oral Presentation: DMT05
Abstract Oral Presentation

Outcomes of COVID-19 in Patients With Relapsing Multiple Sclerosis Receiving Ofatumumab: Data From the ALITHIOS Study and Post-marketing Surveillance

Poster Presentation: DMT13
Abstract

OLIKOS Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients who Transition From Intravenous Anti-CD20 Therapy

Poster Presentation: DMT43
Abstract

Comparable Ofatumumab Treatment Outcomes in Patients Across Racial/Ethnic Groups in the ASCLEPIOS I/II and APOLITOS studies

Poster Presentation: DMT63
Abstract

Efficacy of Ofatumumab on Microglial Activity in Patients With Relapsing forms of Multiple Sclerosis: Interim Analysis

Poster Presentation: DMT74
Abstract

AGNOS Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy

Poster Presentation: DMT75
Abstract

Pregnancy Outcomes in Patients With Multiple Sclerosis Following Exposure to Ofatumumab

Poster Presentation:
Abstract Oral Presentation

FINGOLIMOD

Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models

Poster Presentation: DMT42

NON-BRANDED (PORTFOLIO)

Patient-Reported Outcome Measures in Multiple Sclerosis Clinical Trials: Critical Assessment and Insights from People Living with Multiple Sclerosis

Poster Presentation: 7323
Abstract

Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies

Poster Presentation: 7338
Abstract

The Art of the Patient Conversation: Advanced Practice Provider Perspectives to Improve Outcomes in Multiple Sclerosis

Oral Presentation: 7362
Abstract Oral Presentation

National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis

Poster Presentation: MDC05
Abstract

MLR ID: 165102


May 26-Jun 4, 2020, Virtual Meeting
 

Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials

Oral Presentation: DMT03
Abstract

Real-world Findings of Usability and Usefulness of MSProDiscussTM: A Physician-Completed Digital Tool to Evaluate Early Signs of Disease Progression

Abstract

Early Effect of Ofatumumab on B-Cell Counts and MRI Activity in Relapsing Multiple Sclerosis Patients: Results From the APLIOS Study

Poster Presentation: DXT02
Abstract

Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials

Abstract

Injection-Related Reactions With Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Pooled Analysis of the Phase 3 ASCLEPIOS I and II Trials

Poster Presentation: DXT61
Abstract

Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis Patients from the Phase 3 ASCLEPIOS I and II Trials

Abstract

Compliance to Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis

Poster Presentation: DXT18
Abstract

Siponimod First-Dose Effects in Patients With SPMS Receiving Concomitant Selective Serotonin Reuptake Inhibitor Therapy

Poster Presentation: DXT04
Abstract

Two Expanded Disability Status Scale Subscales Evaluated in Patients With Relapsing-Remitting or Secondary Progressive Multiple Sclerosis

Poster Presentation: DXT24
Abstract

Orchestrating a New Path for MS Rehabilitation: Empowering Patients Through Both Physical and Music Therapies

Poster Presentation
Abstract

Discussing Multiple Sclerosis (MS) Progression With Patients: Experiences of UK Healthcare Professionals From the SPECTRUM Project

Poster Presentation: PSF07
Abstract
Cookie Settings